In Section A, participants will acquire different doses and schedules of oral ABBV-744 pill to recognize Harmless dosing regimen. Additional individuals will be enrolled on the determined monotherapy dosign program. In Phase B, participants will obtain oral ruxolitinib and ABBV-744 might be given as "insert-on" therapy. In Phase C, participants https://kemalk665vgq7.nizarblog.com/profile